Marie N Becker1, Kevin J Wu2, Laura A Marlow3, Pamela A Kreinest3, Christina A Vonroemeling3, John A Copland3, Christopher R Williams4. 1. Division of Urology, Department of Surgery, College of Medicine-Jacksonville, University of Florida, Jacksonville, FL. Electronic address: Marie.becker@jax.ufl.edu. 2. Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL. 3. Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL. 4. Division of Urology, Department of Surgery, College of Medicine-Jacksonville, University of Florida, Jacksonville, FL.
Abstract
OBJECTIVE: To examine the ability of dual mTORc1/c2 inhibitors in conjunction with lapatinib to function in a synergistic manner to inhibit cell proliferation and anchorage-independent growth in bladder cancer cell lines. MATERIALS AND METHODS: We examined patient tumor samples for overexpression of pS6, p4EBP1, pAkt, and phosphorylated epidermal growth factor receptor (pEGFR) using a tissue microarray containing 84 cases. Three bladder cancer cell lines, T24, HT1376, and UM-UC-3, were analyzed for cell proliferation after treatment with mTORc1/c2 inhibitors OSI-027 or PP242. Western blots were used to verify that the drugs were inhibiting phosphorylation of target proteins within the mTOR pathway, and they were compared with rapamycin inhibition. We also analyzed cell proliferation and anchorage-independent growth after treatment with OSI-027 and lapatinib in combination. PARP cleavage and autophagic flux were measured by examining levels of LC3B and p62 by western blotting. RESULTS: Tumor samples show increased expression of pEGFR (38% vs. 8%) and HER2 (38% vs. 4%) and decreased expression of pAkt S473 (7.5% vs. 29%) and pAkt T308 (50% vs. 84%) relative to normal tissue. Significant differences between normal and tumor samples for staining with pEGFR (P = 0.0188), HER 2 (P = 0.0017), pATK S473 (P = 0.0128), and pAkt T308 (P = 0.0015) is observed. Expression of proteins within the EGFR/HER2 pathway or within the mTOR pathway is correlated. No correlation was found between staining and tumor stage. OSI-027 and PP242 diminish cell proliferation in all 3 cell lines with IC50 values ranging from 0.63 to 17.95µM. Both drugs inhibit phosphorylation of both mTORc1 and mTORc2 pathway components. OSI-027 and lapatinib inhibit cell proliferation and anchorage-independent growth in a synergistic manner. One cell line exhibited apoptosis in response to combination drug treatment, whereas the other 2 cell lines have increased levels of autophagy indicative of resistance to apoptosis. CONCLUSIONS: The combination of OSI-027 and lapatinib results in antitumor synergy and further exploration of this combination should be undertaken.
OBJECTIVE: To examine the ability of dual mTORc1/c2 inhibitors in conjunction with lapatinib to function in a synergistic manner to inhibit cell proliferation and anchorage-independent growth in bladder cancer cell lines. MATERIALS AND METHODS: We examined patienttumor samples for overexpression of pS6, p4EBP1, pAkt, and phosphorylated epidermal growth factor receptor (pEGFR) using a tissue microarray containing 84 cases. Three bladder cancer cell lines, T24, HT1376, and UM-UC-3, were analyzed for cell proliferation after treatment with mTORc1/c2 inhibitors OSI-027 or PP242. Western blots were used to verify that the drugs were inhibiting phosphorylation of target proteins within the mTOR pathway, and they were compared with rapamycin inhibition. We also analyzed cell proliferation and anchorage-independent growth after treatment with OSI-027 and lapatinib in combination. PARP cleavage and autophagic flux were measured by examining levels of LC3B and p62 by western blotting. RESULTS:Tumor samples show increased expression of pEGFR (38% vs. 8%) and HER2 (38% vs. 4%) and decreased expression of pAkt S473 (7.5% vs. 29%) and pAkt T308 (50% vs. 84%) relative to normal tissue. Significant differences between normal and tumor samples for staining with pEGFR (P = 0.0188), HER 2 (P = 0.0017), pATK S473 (P = 0.0128), and pAkt T308 (P = 0.0015) is observed. Expression of proteins within the EGFR/HER2 pathway or within the mTOR pathway is correlated. No correlation was found between staining and tumor stage. OSI-027 and PP242 diminish cell proliferation in all 3 cell lines with IC50 values ranging from 0.63 to 17.95µM. Both drugs inhibit phosphorylation of both mTORc1 and mTORc2 pathway components. OSI-027 and lapatinib inhibit cell proliferation and anchorage-independent growth in a synergistic manner. One cell line exhibited apoptosis in response to combination drug treatment, whereas the other 2 cell lines have increased levels of autophagy indicative of resistance to apoptosis. CONCLUSIONS: The combination of OSI-027 and lapatinib results in antitumor synergy and further exploration of this combination should be undertaken.
Authors: Shripad V Bhagwat; Prafulla C Gokhale; Andrew P Crew; Andy Cooke; Yan Yao; Christine Mantis; Jennifer Kahler; Jennifer Workman; Mark Bittner; Lorina Dudkin; David M Epstein; Neil W Gibson; Robert Wild; Lee D Arnold; Peter J Houghton; Jonathan A Pachter Journal: Mol Cancer Ther Date: 2011-06-14 Impact factor: 6.261
Authors: Igor Makhlin; Jiaru Zhang; Christopher J Long; Karthik Devarajan; Yan Zhou; Andres J Klein-Szanto; Min Huang; Jonathan Chernoff; Stephen A Boorjian Journal: BJU Int Date: 2010-11-02 Impact factor: 5.588
Authors: Donna E Hansel; Eric Platt; Mohammed Orloff; Jyoti Harwalker; Swathi Sethu; Jessica L Hicks; Angelo De Marzo; Roxanne E Steinle; Eric D Hsi; Dan Theodorescu; Christina B Ching; Charis Eng Journal: Am J Pathol Date: 2010-04-15 Impact factor: 4.307
Authors: Mamta Gupta; Andrea E Wahner Hendrickson; Seong Seok Yun; Jing Jing Han; Paula A Schneider; Brian D Koh; Mary J Stenson; Linda E Wellik; Jennifer C Shing; Kevin L Peterson; Karen S Flatten; Allan D Hess; B Douglas Smith; Judith E Karp; Sharon Barr; Thomas E Witzig; Scott H Kaufmann Journal: Blood Date: 2011-11-11 Impact factor: 22.113
Authors: Adel H Jebar; Carolyn D Hurst; Darren C Tomlinson; Colin Johnston; Claire F Taylor; Margaret A Knowles Journal: Oncogene Date: 2005-08-04 Impact factor: 9.867
Authors: Matthew R Janes; Jose J Limon; Lomon So; Jing Chen; Raymond J Lim; Melissa A Chavez; Collin Vu; Michael B Lilly; Sharmila Mallya; S Tiong Ong; Marina Konopleva; Michael B Martin; Pingda Ren; Yi Liu; Christian Rommel; David A Fruman Journal: Nat Med Date: 2010-01-13 Impact factor: 53.440
Authors: Christian Wülfing; Jean-Pascal H Machiels; Dirk J Richel; Marc-Oliver Grimm; Uwe Treiber; Marco R De Groot; Philippe Beuzeboc; Roma Parikh; Frank Pétavy; Iman A El-Hariry Journal: Cancer Date: 2009-07-01 Impact factor: 6.860
Authors: Joaquin Mateo; David Olmos; Herlinde Dumez; Srinivasu Poondru; Nancy L Samberg; Sharon Barr; Jan M Van Tornout; Fei Jie; Shahneen Sandhu; Daniel S Tan; Victor Moreno; Patricia M LoRusso; Stan B Kaye; Patrick Schöffski Journal: Br J Cancer Date: 2016-03-22 Impact factor: 7.640